Mary Beth Scholand,
MD
Languages Spoken: English
Dr. Mary Beth Scholand, MD is an associate professor in Pulmonary Medicine. Her research and clinical interest is Interstitial Lung Disease. This interest encompasses Idiopathic Pulmonary Fibrosis, Autoimmune Lung Diseases and Sarcoidosis. She is the Director of the Interstitial Lung Disease Clinic. She runs clinical trials focused on a cure for Idiopathic Pulmonary Fibrosis. In addition, her research focuses on phenotypic factors and genetic factors associated with Chronic Obstructive Pulmonary Diseases and Interstitial Lung Diseases.
Clinical Locations
801-213-3200
801-213-4500
801-581-2000
Pulmonary, Clinic 3
801-581-7806
Fax: (801) 585-3555
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Pulmonary |
| Board Certification | American Board of Internal Medicine (Sub: Pulmonary Disease) National Board of Medical Examiners |
Patient Rating
The Patient Rating score is an average of all responses to care provider related questions on our nationally-recognized Press Ganey Patient Satisfaction Survey.
Responses are measured on a scale of 1 to 5 with 5 being the best score.
Likelihood of recommending care provider
4.9/ 5
Care provider's explanation of condition/problem
4.9/ 5
Care provider's effort to include me in decisions
4.9/ 5
Wait time at clinic
4.7/ 5
Care provider's concern for questions & worries
4.9/ 5
Patient Comments
Patient comments are gathered from our Press Ganey Patient Satisfaction Survery and displayed in their entirety. Patients are de-identified for confidentiality and patient privacy.
UofU Patient
November 12, 2022
University Hospital
Dr. Scholand is a fantastic Doctor!!!! She listens, addresses any concerns, makes sure that at no time is there any questions left unanswered and is always very kind and explains everything so that you understand everything that is going on with your treatment and diagnosis.
UofU Patient
October 30, 2022
Farmington Health Center
Have been with provider for awhile. Have good working relations .
UofU Patient
October 28, 2022
South Jordan Health Center
She did a special good work
UofU Patient
October 28, 2022
Sugar House Health Center
Dr. Scholand is excellent and very concerned with my health and will do anything she can to help.
UofU Patient
October 16, 2022
FARMINGTON HEALTH CENTER
Excellent
UofU Patient
October 16, 2022
FARMINGTON HEALTH CENTER
Dr Scholand was absolutely great!
UofU Patient
October 08, 2022
FARMINGTON HEALTH CENTER
Dr. Scholand is the best when it comes to explaining and recommending treatments.
UofU Patient
October 04, 2022
UH HOSPITALS AND CLINICS
Dr Scholand always listens well, explains well, and kindly answers all my questions. She also always includes me in decisions and formulating a plan. I REALLY appreciate her. I do wish the coordination that took place with my rheumatologist as it was when Dr. Frech was there was still in place. I think that was a huge benefit that is hard to replace when dealing with chronic, multi-faceted disease.
UofU Patient
October 02, 2022
FARMINGTON HEALTH CENTER
Good
UofU Patient
September 28, 2022
SOUTH JORDAN HEALTH CENTER
I have already told two others about. U of U. Lung Dept. They are going to contact the Hospital for help.
UofU Patient
September 23, 2022
SUGAR HOUSE HEALTH CENTER
I'm so grateful to have found Dr Scholand. Her knowledge on my condition was so good. She explained things to me and included both my husband and I in decisions. She spoke to both of us. And really listened to both of us.
UofU Patient
September 21, 2022
FARMINGTON HEALTH CENTER
I am a long time established patient of Dr. Scholand and she is a Great doctor as well as a special friend.
UofU Patient
September 15, 2022
SOUTH JORDAN HEALTH CENTER
Dr Sholand is an amazing Dr I trust her completely. I feel she really cares about my care.
UofU Patient
September 04, 2022
FARMINGTON HEALTH CENTER
Dr. Scholand always thinks of new ways or treatments to make my life easier.
UofU Patient
August 28, 2022
FARMINGTON HEALTH CENTER
Outstanding doctor
UofU Patient
August 12, 2022
SUGAR HOUSE HEALTH CENTER
Mary Beth is a wonderful, profesional and I really get in shock because she remembers things about me as a patient that I wasn't expecting. She is a very loving and graceful person that take car of patients not only with her knowledge, but with her heart. Great experience always!!!
UofU Patient
August 06, 2022
SUGAR HOUSE HEALTH CENTER
I have had Dr. Scholand since I was 1st seen at the University of Utah over 12 years ago. She is the only reason I chose Healthy U as my provider. I could not see her under any other insurance option I had at the time. I have remained with Healthy U because it is great secondary insurance for me and I still have Dr. Scholand!!
UofU Patient
August 04, 2022
SOUTH JORDAN HEALTH CENTER
Dr Scholand was excellent. Very knowledgeable, explained things thoroughly, very personable and compassionate. One of the best physician visits I've ever had. I'm so impressed with her efficiency snd follow through snd communication. 5 STAR
UofU Patient
July 30, 2022
UH HOSPITALS AND CLINICS
Have been with this team since 2015.
UofU Patient
July 21, 2022
UH HOSPITALS AND CLINICS
I wish I would have asked a few more questions
UofU Patient
July 17, 2022
FARMINGTON HEALTH CENTER
Very satisfied
UofU Patient
July 16, 2022
UH HOSPITALS AND CLINICS
Dr Scholand is amazing
UofU Patient
July 14, 2022
UH HOSPITALS AND CLINICS
Good
UofU Patient
July 01, 2022
SUGAR HOUSE HEALTH CENTER
Dr. Scholand went all out to answer all my questions and to calm my concerns. She made sure I was part of the future plans by encouraging my input. I am extremely happy with my experiences with her.
UofU Patient
June 23, 2022
SOUTH JORDAN HEALTH CENTER
Pharmacy was very helpful
UofU Patient
June 22, 2022
SUGAR HOUSE HEALTH CENTER
The physician is very patient centered in her care delivery.
UofU Patient
June 07, 2022
SUGAR HOUSE HEALTH CENTER
Dr. Scholand is one of the most caring doctors I have ever met.
UofU Patient
June 04, 2022
SUGAR HOUSE HEALTH CENTER
I am glad I decided to seek out another opinion from her. She is very knowledgeable and wants to get to cause of fibrosis so she can select best possible treatment.
UofU Patient
May 29, 2022
FARMINGTON HEALTH CENTER
Good
Dr. Mary Beth Scholand, MD is an associate professor in Pulmonary Medicine. Her research and clinical interest is Interstitial Lung Disease. This interest encompasses Idiopathic Pulmonary Fibrosis, Autoimmune Lung Diseases and Sarcoidosis. She is the Director of the Interstitial Lung Disease Clinic. She runs clinical trials focused on a cure for Idiopathic Pulmonary Fibrosis. In addition, her research focuses on phenotypic factors and genetic factors associated with Chronic Obstructive Pulmonary Diseases and Interstitial Lung Diseases.
Academic Locations
Research Statement
Dr. Mary Beth Scholand is an Associate Professor in Pulmonary Medicine. Her clinical practice primarily focuses on interstitial lung disease (ILD) and she is the Director of the ILD Clinic. ILD is a disease category that encompasses many pulmonary conditions, including idiopathic pulmonary fibrosis (IPF), autoimmune lung diseases, and sarcoidosis. Dr. Scholand is the principal investigator on numerous clinical trials which aim to find a treatment for pulmonary fibrosis (both idiopathic and autoimmune in etiology), and is a co-investigator in NIH-funded studies on IPF and chronic obstructive pulmonary disease. In addition, Dr. Scholand studies the relationship between genetic and phenotypic variation to identify genes that significantly elevate the risk of developing ILD, and thus to find new therapeutic targets.
Board Certification and Academic Information
| Academic Departments | Internal Medicine
-
Associate Professor |
| Academic Divisions | Pulmonary |
| Board Certification | American Board of Internal Medicine (Sub: Pulmonary Disease) National Board of Medical Examiners |
Research Interests
- Pulmonary Fibrosis
Education History
| Fellowship | University of Utah School of Medicine Pulmonary Medicine Fellow, 2002 |
| Residency | Barnes Hospital Internal Medicine Resident, 1993 |
| Internship | Barnes Hospital Internal Medicine Intern, 1991 |
| Professional Medical | Washington University Medicine M.D., 1990 |
| Undergraduate | Northwestern University B.S., 1986 |
Selected Publications - Journal Articles
Journal Article
- Saketkoo LA LA, Jensen K, Nikoletou D, Newton JJ, Rivera FJ, Howie M, Reese RK, Goodman M, Hart PB, Bembry W, Russell A, Lian I, Lammi MR, Scholand Mb MB, Russell Am AM (2022). Sarcoidosis Illuminations on Living During COVID-19: Patient Experiences of Diagnosis, Management, and Survival Before and During the Pandemic. J Patient Exp, 9, 23743735221075556.
- Lee J, White E, Freiheit E, Scholand MB, Strek ME, Podolanczuk AJ, Patel NM, Pulmonary Fibrosis Foundation (2022). Cough-specific Quality of Life Predicts Disease Progression Among Patients with Interstitial Lung Disease: Data from the Pulmonary Fibrosis Foundation Patient Registry. Chest.
- Gupta R, Baughman RP, Nathan SD, Wells AU, Kouranos V, Alhamad EH, Culver DA, Barney J, Carmona EM, Cordova FC, Huitema M, Scholand MB, Wijsenbeek M, Ganesh S, Birring SS, Price LC, Wort SJ, Shlobin OA (2022). The six-minute walk test in sarcoidosis associated pulmonary hypertension: Results from an international registry. Respir Med, 196, 106801.
- Rahaghi FF, Kolaitis NA, Adegunsoye A, de Andrade J, Flaherty KR, Lancaster L, Lee JS, Levine D, Preston IR, Safdar Z, Saggar R, Sahay S, Scholand MB, Shlobin O, Zisman DA, Nathan SD (2022). Screening Strategies for Pulmonary Hypertension in Patients With Interstitial Lung Disease: A Multidisciplinary Delphi Study. Chest, 162, 145-155.
- Huitema MP, Post MC, Grutters JC, Wells AU, Kouranos V, Shlobin OA, Nathan SD, Culver DA, Barney J, Gupta R, Carmona E, Alhamad EH, Scholand MB, Wijsenbeek M, Ganesh S, Lower EE, Engel PJ, Baughman RP (2022). Echocardiographic estimate of pulmonary artery pressure in sarcoidosis patients - real world data from a multi-national study. Sarcoidosis Vasc Diffuse Lung Dis, 38(4), e2021032.
- Lasky JA, Case A, Unterman A, Kreuter M, Scholand MB, Chaudhary S, Lofaro LR, Johnson M, Huang J, Bhorade SM, Kennedy GC (2021). The Impact of the Envisia Genomic Classifier in the Diagnosis and Management of Patients with Idiopathic Pulmonary Fibrosis. Ann Am Thorac Soc, 19, 916-924.
- Pettersson H, Alexanderson H, Poole JL, Varga J, Regardt M, Russell AM, Salam Y, Jensen K, Mansour J, Frech T, Feghali-Bostwick C, Varj C, Baldwin N, Heenan M, Fligelstone K, Holmner M, Lammi MR, Scholand MB, Shapiro L, Volkmann ER, Saketkoo LA (2021). Exercise as a multi-modal disease-modifying medicine in systemic sclerosis: An introduction by The Global Fellowship on Rehabilitation and Exercise in Systemic Sclerosis (G-FoRSS). Best Pract Res Clin Rheumatol, 35, 101695.
- Saketkoo LA, Russell AM, Jensen K, Mandizha J, Tavee J, Newton J, Rivera F, Howie M, Reese R, Goodman M, Hart P, Strookappe B, De Vries J, Rosenbach M, Scholand MB, Lammi MR, Elfferich M, Lower E, Baughman RP, Sweiss N, Judson MA, Drent M (2021). Health-Related Quality of Life (HRQoL) in Sarcoidosis: Diagnosis, Management, and Health Outcomes. Diagnostics (Basel), 11(6).
- Martinez FJ, Yow E, Flaherty KR, Snyder LD, Durheim MT, Wisniewski SR, Sciurba FC, Raghu G, Brooks MM, Kim DY, Dilling DF, Criner GJ, Kim H, Belloli EA, Nambiar AM, Scholand MB, Anstrom KJ, Noth I, CleanUP-IPF Investigators of the Pulmonary Trials Cooperative (2021). Effect of Antimicrobial Therapy on Respiratory Hospitalization or Death in Adults With Idiopathic Pulmonary Fibrosis: The CleanUP-IPF Randomized Clinical Trial. JAMA, 325(18), 1841-1851.
- Maher TM, Costabel U, Glassberg MK, Kondoh Y, Ogura T, Scholand MB, Kardatzke D, Howard M, Olsson J, Neighbors M, Belloni P, Swigris JJ (2021). Phase 2 trial to assess lebrikizumab in patients with idiopathic pulmonary fibrosis. Eur Respir J, 57(2).
- Richeldi L, Scholand MB, Lynch DA, Colby TV, Myers JL, Groshong SD, Chung JH, Benzaquen S, Nathan SD, Davis JR, Schmidt SL, Hagmeyer L, Sonetti D, Hetzel J, Criner GJ, Case AH, Ramaswamy M, Calero K, Gauhar UA, Patel NM, Lancaster L, Choi Y, Pankratz DG, Walsh PS, Lofaro LR, Huang J, Bhorade SM, Kennedy GC, Martinez FJ, Raghu G (2020). Utility of a Molecular Classifier as a Complement to High-Resolution Computed Tomography to Identify Usual Interstitial Pneumonia. Am J Respir Crit Care Med, 203(2), 211-220.
- Swigris JJ, Andrae DA, Churney T, Johnson N, Scholand MB, White ES, Matsui A, Raimundo K, Evans CJ (2020). Development and Initial Validation Analyses of the Living with Idiopathic Pulmonary Fibrosis Questionnaire. Am J Respir Crit Care Med, 202(12), 1689-1697.
- Rahaghi FF, Safdar Z, Brown AW, de Andrade JA, Flaherty KR, Kaner RJ, King CS, Padilla ML, Noth I, Scholand MB, Shifren A, Nathan SD (2020). Expert consensus on the management of adverse events and prescribing practices associated with the treatment of patients taking pirfenidone for idiopathic pulmonary fibrosis: a Delphi consensus study. BMC Pulm Med, 20(1), 191.
- Baughman RP, Scholand MB, Rahaghi FF (2020). Clinical phenotyping: role in treatment decisions in sarcoidosis. Eur Respir Rev, 29(155).
- Rahaghi FF, Baughman RP, Saketkoo LA, Sweiss NJ, Barney JB, Birring SS, Costabel U, Crouser ED, Drent M, Gerke AK, Grutters JC, Hamzeh NY, Huizar I, Ennis James W 4th, Kalra S, Kullberg S, Li H, Lower EE, Maier LA, Mirsaeidi M, Mller-Quernheim J, Carmona Porquera EM, Samavati L, Valeyre D, Scholand MB (2020). Delphi consensus recommendations for a treatment algorithm in pulmonary sarcoidosis. Eur Respir Rev, 29(155).
- Rahaghi FF, Sweiss NJ, Saketkoo LA, Scholand MB, Barney JB, Gerke AK, Lower EE, Mirsaeidi M, OHare L, Rumbak MJ, Samavati L, Baughman RP (2020). Management of repository corticotrophin injection therapy for pulmonary sarcoidosis: a Delphi study. Eur Respir Rev, 29(155).
- Saketkoo LA, Scholand MB, Lammi MR, Russell AM (2020). Patient-reported outcome measures in systemic sclerosis-related interstitial lung disease for clinical practice and clinical trials. J Scleroderma Relat Disord, 5(2 Suppl), 48-60.
- Richeldi L, Fernndez Prez ER, Costabel U, Albera C, Lederer DJ, Flaherty KR, Ettinger N, Perez R, Scholand MB, Goldin J, Peony Yu KH, Neff T, Porter S, Zhong M, Gorina E, Kouchakji E, Raghu G (2019). Pamrevlumab, an anti-connective tissue growth factor therapy, for idiopathic pulmonary fibrosis (PRAISE): a phase 2, randomised, double-blind, placebo-controlled trial. Lancet Respir Med, 8(1), 25-33.
- Patel NM, Kulkarni T, Dilling D, Scholand MB, Interstitial and Diffuse Lung Disease Network Steering Committee (2019). Preoperative Evaluation of Patients With Interstitial Lung Disease. Chest, 156(5), 826-833.
- Wuyts W, Antin-Ozerkis D, Huggins JT, LaCamera PP, Spagnolo P, Vakov M, Wijsenbeek MS, Polman B, Kirchgaessler KU, Scholand MB (2019). Serious adverse events in patients with idiopathic pulmonary fibrosis in the placebo arms of 6 clinical trials. Respir Med, 150, 120-125.